Interestingly, while each of these melanoma models harbored a BRAF mutation, single-agent treatment with an experimental direct OXPHOS inhibitor, IACS-010759, significantly improved the survival of mice- and had greater effects on brain metastases than on lung metastases or primary tumors. The gene discussed is BRAF; the disease is melanoma.